Ophthalmic Drugs Market By Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Pune, India -- (SBWire) -- 05/08/2019 --The Global Ophthalmic Drugs Market size is estimated to grow at CAGR above 4.2% over the forecast time frame 2019-2026 and reach the market value around USD 40 billion by 2026.

The growth of the ophthalmic therapeutic market is driven by increased funding from public and private bodies to research on ocular disorders, with the presence of strongly emerging pipeline drugs. Shire and Parion Sciences, for example, collaborated to develop and marketP-321, which is used in adult dry-eye diseases. Furthermore, approval for new products is expected to promote the market for the treatment of eye disorders.

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1323

For example, Nicox was approved for the treatment of ocular itching related to allergic conjunctivitis by FDA for ZERVIATE (cetirizine ophthalmic solution) in 2017. Key companies, including Bausch & Lomb Inc. and Pfizer, Inc., Novartis AG, are involved in fusions & acquisitions in order to increase their market share. This is the very first ocular version of antihistamine. Abbott Medical Optics, Inc. was acquired in 2017 by Johnson & Johnson Services, Inc. With this acquisition, the entire Abbott Medical Optics, Inc. product range will be sold under the name Johnson&Johnson including consumer visual health, laser refractive surgery and cataract surgery.

Growth Factors

Other key factors that increase the market size of ophthalmic drugs include a world-wide high prevalence of glaucoma and an increase in the transition to combination therapies to treat glaucoma. The population dynamics around the globe also contribute to the growth of the market. However, this growth is impeded by the risk of side effects related to ophthalmic medicines and the longer schedules for new ophthalmic medicine. In addition, increased investment by emerging-economy market players offers lucrative market growth opportunities in the near future.

Market Snapshots

In 2018, the anti-VEGF agent is leading the market and, due to the widespread use of it for eye conditions such as age related macular degeneration and diabetic retinopathy, is provisionally the fastest CAGR of more than 7.5% between 2019 and 2026.

Retinal disorder has been estimated as the largest segment and, due to the increasing prevalence of diabetic retinopathy, is considered to be the fastest-growing segment of the disease.

Eye drops led the market in 2018, with the most cost-effective CAGR compared to other forms of dosage being projected.

The largest share of prescription drugs was in 2018, as they are seen as more effective.

Due to the easy accessibility of OTC drugs, OTC type is said to be the fastest growing segment during the predicted time period.

The market was led by North America in 2018 as demand for the treatment of dry eyes and glaucoma was growing.

Different organizations' awareness programs and the increase in disposable incomes are projected to be the most rapidly growing regional market during the forecast period.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/ophthalmic-drugs-market

Key Players & Strategies

The Ophthalmic Drugs market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players of the market are ALLERGAN PLC; Pfizer, Inc.; Santen Pharmaceutical Co., Ltd.; Johnson & Jean - Services, Inc.; Merck Sharp & Dohme Corp.; and Genentech, Inc. AG; Bausch & Lomb, Inc.; Regeneron Pharmaceutical, Inc., among others.

Santen Pharmaceuticals has been approved for the treatment of Severe Vernal Keratoconjunctivitis in pediatric patients by the Committee of Human Medicinal Products (CHMP) in 2017 for the marketing of its product, cyclosporine, in Europe. In the same year Genentech, Inc. was approved for the treatment of diabetic retinopathy by the FDA for its product, Lucentis, to improve its product portfolio.

In addition to improving their profitability and gaining a competitive edge on other players, the key players on the Ophthalmic Drugs market employ new ideas and concepts, improve production processes and improve the existing set of products. The key players therefore have taken product development as their key development strategy to be consistent with end users ' demands.

Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Ophthalmic Drugs
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Ophthalmic Drugs Market By Drug Class Outlook
1.2.2.1. Global Ophthalmic Drugs Market Revenue and Growth Rate Comparison By Drug Class Outlook (2015-2026)
1.2.2.2. Global Ophthalmic Drugs Market Revenue Share By Drug Class Outlook in 2017
1.2.2.3. Antiallergy
1.2.2.4. Anti-Vascular Endothelial Growth Factor (Anti-Vegf) Agents
1.2.2.5. Anti-inflammatory
1.2.2.5.1. Nonsteroidal Drugs
1.2.2.5.2. Steroidal Drugs
1.2.2.6. Antiglaucoma
1.2.2.7. Others
1.2.3. Ophthalmic Drugs Market By Disease Outlook
1.2.3.1. Global Ophthalmic Drugs Market Revenue and Growth Rate Comparison By Disease Outlook (2015-2026)
1.2.3.2. Global Ophthalmic Drugs Market Revenue Share By Disease Outlook in 2017
1.2.3.3. Dry Eye
1.2.3.4. Allergies
1.2.3.5. Glaucoma
1.2.3.6. Inflammation/Infection
1.2.3.7. Retinal Disorders
1.2.3.8. Uveitis
1.2.3.9. Others
1.2.4. Ophthalmic Drugs Market By Dosage Form
1.2.4.1. Global Ophthalmic Drugs Market Revenue and Growth Rate Comparison By Dosage Form (2015-2026)
1.2.4.2. Global Ophthalmic Drugs Market Revenue Share By Dosage Form in 2017
1.2.4.3. Gels
1.2.4.4. Eye Solutions
1.2.4.5. Capsules & Tablets
1.2.4.6. Eye Drops
1.2.4.7. Ointments
1.2.4.8. Others
1.2.5. Ophthalmic Drugs Market By Product Type
1.2.5.1. Global Ophthalmic Drugs Market Revenue and Growth Rate Comparison By Product Type (2015-2026)
1.2.5.2. Global Ophthalmic Drugs Market Revenue Share By Product Type in 2017
1.2.5.3. Prescription Drugs
1.2.5.4. OTC Drugs
1.2.5.5. Others
1.2.6. Ophthalmic Drugs Market by Geography
1.2.6.1. Global Ophthalmic Drugs Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Ophthalmic Drugs Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Ophthalmic Drugs Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Ophthalmic Drugs Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Ophthalmic Drugs Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Ophthalmic Drugs Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter's Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Ophthalmic Drugs Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Ophthalmic Drugs Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Ophthalmic Drugs Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Ophthalmic Drugs Major Manufacturers in 2017

CHAPTER 4. Ophthalmic Drugs Market By Drug Class Outlook

4.1. Global Ophthalmic Drugs Revenue By Drug Class Outlook
4.2. Antiallergy
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Anti-Vascular Endothelial Growth Factor (Anti-Vegf) Agents
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Anti-inflammatory
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4.3. Nonsteroidal Drugs
4.4.4. Steroidal Drugs
4.5. Antiglaucoma
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Others
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. Ophthalmic Drugs Market By Disease Outlook

5.1. Global Ophthalmic Drugs Revenue By Disease Outlook
5.2. Dry Eye
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Allergies
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Glaucoma
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Inflammation/Infection
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Retinal Disorders
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.7. Uveitis
5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.8. Others
5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. Ophthalmic Drugs Market By Dosage Form

6.1. Global Ophthalmic Drugs Revenue By Dosage Form
6.2. Gels
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Eye Solutions
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Capsules & Tablets
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Eye Drops
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.6. Ointments
6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.7. Others
6.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. Ophthalmic Drugs Market By Product Type

7.1. Global Ophthalmic Drugs Revenue By Product Type
7.2. Prescription Drugs
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. OTC Drugs
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Others
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 8. North America Ophthalmic Drugs Market By Country

8.1. North America Ophthalmic Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. North America Ophthalmic Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Ophthalmic Drugs Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 9. Europe Ophthalmic Drugs Market By Country

9.1. Europe Ophthalmic Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Europe Ophthalmic Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 10. Asia-Pacific Ophthalmic Drugs Market By Country

10.1. Asia-Pacific Ophthalmic Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Asia-Pacific Ophthalmic Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
10.8.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 11. Latin America Ophthalmic Drugs Market By Country

11.1. Latin America Ophthalmic Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Latin America Ophthalmic Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 12. Middle East Ophthalmic Drugs Market By Country

12.1. Middle East Ophthalmic Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Middle East Ophthalmic Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 13. Africa Ophthalmic Drugs Market By Country

13.1. Africa Ophthalmic Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Africa Ophthalmic Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Drug Class Outlook, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 14. COMPANY PROFILE

14.1. Allergan Plc
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Pfizer, Inc.
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. Santen Pharmaceutical Co., Ltd.
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. Johnson & Jean - Services, Inc.
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Merck Sharp & Dohme Corp.
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Genentech, Inc. AG
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Bausch & Lomb, Inc.
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. Regeneron Pharmaceutical, Inc.
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. Others
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies

CHAPTER 15. RESEARCH APPROACH

15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope

INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/1323

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report - https://www.acumenresearchandconsulting.com/buy-now/0/1323

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen Research and Consulting:
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.